Complex Protein may Help HIV Vaccine Development
Scientists at Duke University have taken aim at what may be an Achilles' heel of the HIV virus.
Scientists at Duke University have taken aim at what may be an Achilles' heel of the HIV virus.
‘An experimental HIV vaccine regimen will soon be tested in a large-scale clinical trial. This could lead to the first licensed vaccine against the virus that causes AIDS.’
Tweet it Now
Both trials are funded by the National Institutes of Health and Infectious Diseases, or NIAID, and the Bill & Melinda Gates Foundation and conducted by the NIAID-funded HIV Vaccine Trials Network, which is headquartered at Fred Hutchinson Cancer Research Center. Fred Hutch is home to the largest HIV vaccine trials network in the world. Larry Corey, president and director emeritus of the Fred Hutchinson Cancer Research Center and principal investigator for the HIV Vaccine Trials Network, is available for interviews. In an op-ed piece, he and co-author David Baltimore addressed the common misperception that the 'AIDS crisis is over', and emphasized the critical need for a vaccine.
Source-Newswise
Feuding Antibodies Blocked High-profile HIV Vaccine Trial
A high-profile HIV vaccine trial that was shown to work in just under a third of patients may have been hindered by feuding antibodies, says US researchers.
A high-profile HIV vaccine trial that was shown to work in just under a third of patients may have been hindered by feuding antibodies, says US researchers.
In Infants, HIV Vaccines Elicit Immune Response
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers.
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers.
Experimental HIV Vaccine Candidate may Generate Immune Response to Block Infection
An experimental vaccine that contains a special class of immune system molecules may have the potential to stimulate the immune system to block HIV infection.
An experimental vaccine that contains a special class of immune system molecules may have the potential to stimulate the immune system to block HIV infection.
